

Application No. 09/926,286
Reply to Office Action Dated January 15, 2004
Amendment Dated June 15, 2004

Amendments to the Claims:

This Listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for reducing invasiveness and/or migration of malignant cells in a patient in need of ~~such a~~ reduction in the invasiveness and/or migration of malignant cells comprising

administering to the patient an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in an invasiveness and/or migration of malignant cells reducing effective amount, and a pharmaceutically acceptable carrier therefor.

2. (Previously presented) The method of claim 1 wherein said at least one physiologically equivalent derivative of alpha lipoic acid is a salt, ester or inclusion complex.

3. (Previously presented) The method of claim 2 wherein said salt is a pharmaceutically acceptable salt.

4. (Previously presented) The method of claim 1 wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof is administered orally, intravenously or subcutaneously.

Application No. 09/926,286

Reply to Office Action Dated January 15, 2004

Amendment Dated June 15, 2004

5. (Previously presented) The method of claim 1 wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof is administered topically, rectally or by inhalation.

6. (Previously presented) The method of claim 1, wherein said active ingredient is administered in a daily dose of about 0.5 to about 5g.

7. (Previously presented) The method of claim 1, wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof reduces invasiveness of malignant cells.

8. (Previously presented) The method of claim 1, wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof reduces migration of malignant cells.

9. (Currently amended) A method for promoting adhesion of malignant cells in a patient in need of such a promotion in the adhesion of malignant cells comprising

administering to the patient a composition comprising an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in an adhesion of malignant cells promoting effective amount, and a pharmaceutically acceptable carrier therefor.

10. (Previously presented) A method according to claim 10, wherein said adhesion is adhesion to a

Application No. 09/926,286
Reply to Office Action Dated January 15, 2004
Amendment Dated June 15, 2004

basal membrane.

11. (Currently amended) A method for reducing metastasis in a patient in need of ~~such treatment~~
a reduction of metastasis comprising

administering to the patient a composition comprising an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in a metastasis reducing effective amount, and a pharmaceutically acceptable carrier therefor.

12. (Previously presented) The method of claim 11 wherein said at least one physiologically equivalent derivative of alpha lipoic acid is a salt, ester or inclusion complex.

13. (Previously presented) The method of claim 12 wherein said salt is a pharmaceutically acceptable salt.

14. (Previously presented) The method of claim 11 wherein said composition is administered orally, intravenously or subcutaneously.

15. (Previously presented) The method of claim 11 wherein said composition is administered topically, rectally or by inhalation.

Application No. 09/926,286

Reply to Office Action Dated January 15, 2004

Amendment Dated June 15, 2004

16. (Previously presented) The method of claim 11, wherein said composition is administered in a daily dose of about 0.5 to about 5g.

17. (Previously presented) The method of claim 11, wherein metastasis is prevented.